Trigeminal neuralgia is treated primarily with medication, and most people start with an anticonvulsant drug that calms the nerve signals responsible for the pain. When medication stops working or causes intolerable side effects, several surgical and procedural options can provide lasting relief. The right approach depends on how well you respond to drugs, your overall health, and how severely the condition affects your daily life.
The pain itself is distinctive: brief, intense jolts that feel like electric shocks on one side of the face, lasting anywhere from a split second to two minutes. These attacks are typically triggered by everyday actions like chewing, talking, brushing your teeth, or even a light breeze on your skin. Understanding the treatment landscape helps you have more productive conversations about what comes next.
Medication as the Starting Point
Carbamazepine is the most widely used first-line drug for trigeminal neuralgia and remains the standard against which everything else is measured. It works by stabilizing overactive nerve signals, and many people experience significant pain reduction within days of reaching an effective dose. Oxcarbazepine, a closely related drug, is often used as an alternative because it tends to cause fewer side effects while working through a similar mechanism.
Both drugs require blood work before you start and during the first few months. Your doctor will check your sodium levels about two weeks after starting, then monthly for the first three months, because these medications can lower sodium to problematic levels. A complete blood count is also monitored, since in rare cases the drugs can suppress the production of white blood cells. If you develop a fever, sore throat, or unusual fatigue while on either medication, those symptoms need prompt attention because they can signal a blood cell problem.
A common frustration is that carbamazepine and oxcarbazepine can cause drowsiness, dizziness, and difficulty concentrating, especially early on. These side effects often improve as your body adjusts, but for some people they remain a dealbreaker.
When First-Line Drugs Aren’t Enough
If carbamazepine or oxcarbazepine alone doesn’t control the pain, there are several next steps. Adding a second medication is a common strategy. Gabapentin and pregabalin are less potent for trigeminal neuralgia but carry fewer side effects, making them useful as add-on drugs or substitutes for people who can’t tolerate the first-line options.
Lamotrigine has shown promise as an add-on to carbamazepine in small trials, though its dose needs to be increased very gradually over weeks to reduce the risk of a serious skin rash. Baclofen, a muscle relaxant, can help some people, and it’s particularly useful for those who also have multiple sclerosis. In one small study, 11 of 15 patients with typical trigeminal neuralgia achieved complete pain relief on baclofen, though the dose needed varied widely from person to person. Adding phenytoin to carbamazepine may help an additional 8% to 20% of people who didn’t respond to carbamazepine alone.
The honest reality is that the evidence behind most second-line drugs comes from very small studies. Treatment at this stage often involves careful trial and error, adjusting combinations and doses until something works or it becomes clear that medication alone won’t be sufficient.
Botulinum Toxin Injections
Botulinum toxin (Botox) injections into the painful area of the face have emerged as an option for people whose pain doesn’t respond well to oral medications. The toxin is injected at multiple points, typically 10 to 20 injection sites spaced about a centimeter apart, following the distribution of pain across the face. Doses in clinical trials have ranged from 25 to 100 units per session.
Response rates are encouraging: between 68% and 86% of treated patients experience meaningful relief, compared to only 15% to 32% of those receiving a placebo. Side effects are generally mild and temporary, most commonly slight facial weakness or swelling near the injection sites. The effects wear off over time, so repeat injections are needed.
Microvascular Decompression Surgery
Microvascular decompression (MVD) is the most definitive surgical treatment and the only one that addresses a root cause of the pain rather than deliberately damaging the nerve. In most cases of classical trigeminal neuralgia, a blood vessel is pressing against the trigeminal nerve where it exits the brainstem. During MVD, a surgeon moves that vessel away and places a small cushion between the two structures.
The results are strong. About 8 to 9 out of 10 people experience significant pain relief soon after the procedure, according to Cleveland Clinic data, and 7 to 8 out of 10 still have relief five years later. Because it requires opening a small window in the skull behind the ear under general anesthesia, MVD is a more involved procedure than the alternatives below. It’s generally offered to people who are healthy enough for surgery and have a clearly identified vessel compressing the nerve on imaging.
Recovery typically involves a few days in the hospital and several weeks before returning to normal activities. The main risks include hearing changes, cerebrospinal fluid leak, and, rarely, stroke or infection. For most candidates, though, the high success rate and the preservation of normal facial sensation make MVD the preferred surgical option.
Percutaneous Procedures
For people who aren’t good candidates for open surgery, or who prefer a less invasive approach, several needle-based procedures can be performed through the cheek while the patient is briefly sedated. All of them work by partially damaging the trigeminal nerve to interrupt pain signals. The trade-off is that some degree of facial numbness is expected and, in fact, is part of how these treatments work.
The three main options are balloon compression (inflating a tiny balloon against the nerve), glycerol injection (injecting a chemical that damages pain fibers), and radiofrequency ablation (using heat to selectively destroy nerve fibers). Each has distinct pros and cons. In a large comparative analysis of nearly 1,000 patients, balloon compression carried a significantly higher risk of jaw weakness and double vision compared to glycerol injection. Glycerol injection, on the other hand, may offer less durable pain relief.
All percutaneous procedures can be repeated if pain returns, which it often does within a few years. A rare but serious complication across all these techniques is a condition called anesthesia dolorosa, where the face becomes numb yet paradoxically painful. This occurs in roughly 0.3% to 2% of cases and is very difficult to treat, which is one reason surgeons typically try the least destructive options first.
Stereotactic Radiosurgery
Gamma Knife radiosurgery delivers a focused beam of radiation to the trigeminal nerve root without any incision at all. It’s the least invasive procedural option and is particularly suitable for older adults or those with medical conditions that make anesthesia risky.
The main drawback is speed. Unlike MVD or percutaneous procedures, which provide immediate or near-immediate relief, radiosurgery takes time. Most patients respond within six months, with a median onset of relief at about two months. The most common side effect is new facial numbness or tingling, which developed in about 8% of patients in one large series and lasted longer than six months. Pain recurrence rates over time are higher than with MVD, and repeat treatments are sometimes needed.
Peripheral Nerve Stimulation
For people who have exhausted standard medications and procedures, peripheral nerve stimulation is a newer option. A small electrode is implanted near a branch of the trigeminal nerve and delivers mild electrical pulses that disrupt pain signals. In a recent case series of 15 patients with implanted stimulators, 80% were still using the device at a median follow-up of 14 months, with an average pain reduction of about 52%. Stimulation targeting the peripheral branches of the trigeminal nerve appears to produce better outcomes than stimulation aimed at the nerve root or ganglion.
This approach doesn’t destroy nerve tissue and is reversible, since the device can be removed. It’s still considered a last-resort option given the limited data, but it represents a meaningful choice for people living with refractory pain who have already been through multiple treatments.
Choosing a Treatment Path
Most treatment plans follow a predictable sequence. You start with carbamazepine or oxcarbazepine, adjust the dose, and add or switch medications if needed. If medications fail or side effects become unmanageable, the next step depends on your specific situation. Younger, healthier patients with a confirmed vascular compression on MRI are often best served by microvascular decompression, which offers the highest long-term success rate and preserves facial sensation. Older patients or those with significant medical risks may do better with a percutaneous procedure or Gamma Knife radiosurgery.
The condition sometimes goes into remission on its own for months or years, then returns. This unpredictable pattern can complicate treatment decisions, since it’s tempting to delay surgery during a good stretch. What matters most is that you understand the full range of options and their trade-offs, so that when pain control becomes the priority, you’re ready to act rather than scrambling for answers.